Figure 1.
![Figure 1. Genomic characterization of DLBCL cell line models and prioritization of BCR/PI3K inhibitors. (A) Alterations in MYD88, CD79B, PTEN (mutation or copy loss), GNA13, HVCN1, and BCL-2 (translocation [structural variant (SV)] or copy-number gain) in a panel of 10 DLBCL cell lines. (B) Cellular proliferation after 72-hour exposure to specific inhibitors of BCR/PI3K signaling (as indicated in the figure). EC50 values in a colorimetric scale: very sensitive (<0.05 μM) in red, sensitive (=1 μM) in white, to resistant (>20 μM) in black. Results were averaged from 4 biological replicates.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/133/1/10.1182_blood-2018-08-872465/9/blood872465f1.png?Expires=1724829373&Signature=zNcE2~4iP5CGveyoWbO3AlmJuUKo2upVXWJt8m7tFw2lkq3ZVYBxVEBvtq1cFi2pvDkjOs2Kws0778zRzKyICQo10QXnmN6VnwlTiPYjDTcEbcA9JNYV4rpt3i5We4oA1r51IgJMjmNl3yf7q4Ry0z-1oW5FFCfSaf2yauMkuDFjbKLB7nPaoYo1GLjxTTqKV93K3DWpJapMHbxWtNNSKQMrV~-MzRIjR9~oR9kW9eBm2GSvt6LXRY9UFDkkvLbCvI78vlCXJ5t1MKRlmz2OMUyEL1befDV0omjjprTr9-puXWpIy5V3tBIuqOkTNkpQDpwmCOXfANHEFu2eI-19gA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Genomic characterization of DLBCL cell line models and prioritization of BCR/PI3K inhibitors. (A) Alterations in MYD88, CD79B, PTEN (mutation or copy loss), GNA13, HVCN1, and BCL-2 (translocation [structural variant (SV)] or copy-number gain) in a panel of 10 DLBCL cell lines. (B) Cellular proliferation after 72-hour exposure to specific inhibitors of BCR/PI3K signaling (as indicated in the figure). EC50 values in a colorimetric scale: very sensitive (<0.05 μM) in red, sensitive (=1 μM) in white, to resistant (>20 μM) in black. Results were averaged from 4 biological replicates.